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Commentary
Thinking About Cancer Causality and
Chemoprevention^
Frank L Meyskens, Jr.3,4,*
Chemoprevention is a strategy used to block the devel-
opment of cancers in humans. Necessarily, the approach
draws its rationale from a multitude of disciplines. The in-
terdisciplinary milieu necessary to conduct chemoprevention
research has muddied, if not obscured to nonaficionados,
the scientific basis of chemoprevention and its relationship
to more established scientific endeavors. Figure 1 presents
chemoprevention in terms of the relationship of cancer etiol-
ogy and biology to prevention and evaluation of diesase end
points.
Chemoprevention interfaces with biology, epidemiology,
and behavioral sciences, with clinical trials serving as the tac-
tical arm of experimental implementation in humans (7). In
this commentary, the implications of concepts and relation-
ships associated with these interfaces are elucidated through
a series of questions. The answers to these questions will im-
pact on the scientific development of chemoprevention over
the next decade.
Questions
What will be the contribution of genetic background to
designing chemoprevention trials?
To date, cancer intervention trials have been based on
risk characteristics of individuals in a population, and subse-
quent trials have measured the outcome for the population
of individuals in the arms of the trial. Consequently, trials
are designed to include large numbers of individuals with
relatively long-term exposure to the intervention. This ap-
proach has been used to assure that trial data are adequate to
demonstrate the significance and power necessary to prove
the validity of study conclusions. There is increasing evi-
dence that cancer risk is intimately associated with genetic
structure at the molecular level (2). Advances in analysis
of the molecular genotype using restriction fragment-length
polymorphisms and other approaches have made identifica-
tion of hereditary diseases at the molecular level possible;
the same approach is likely to be used in the study of most
cancers soon. Investigators have identified genetic polymor-
phisms that appear to give individuals substantially increased
risk for particular cancers. Almost certainly, with continued
advances in molecular biology, epidemiologic studies will
further establish actual baseline risks for most diseases. Phe-
notypic expression of the disease will be shown to range
from absolute (e.g., bilateral retinoblastoma) to unlikely, de-
pending largely on susceptibility of the underlying molecular
structure to permanent mutagenic damage by any particular
initiator.
On the basis of these findings, individuals with a high
genetic risk should be identifiable, and the required sample
size for any particular trial should be markedly reduced.
Individuals at high risk for a disease would be excellent
candidates for a specific primary prevention trial. In addition,
advances in detection of DNA damage (e.g., DNA adduct
formation) may allow identification of individuals who have
both high risk and mutagenic changes in the relevant tissue.
What is the role of epidemiology in a biological model of
disease prevention?
Epidemiologic approaches have identified major dietary
components and cultural practices that affect the phenotypic
expression of many cancers. Additional study of these fac-
tors in individuals at risk, or perhaps in vitro at the cellular
level, may allow new insights into the fundamental processes
and influences operative at the phenotypic level. A better
understanding of the interaction of risk factors and specific
genes should result in a new mechanistic epidemiology at
the molecular level. For example, certain genetic changes
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Figure 1. Relation-
ship of cancer causal-
ity and biology to
prevention and eval-
uation of disease end
points.
may result in functioning proteins that exhibit subtle differ-
ences from the normal and interact differentially in particular
phenotypes to produce an enhanced risk for abnormal pro-
liferation (3).
Another unexplored area is the epidemiology of preneo-
plastic growth, which offers a rich opportunity for novel re-
search. Little is known about what causes preneoplastic or
metaplastic lesions to form or to evolve into frank malignan-
cies. It is known, however, that cigarette smoking, exposure
to ultraviolet light, and use of alcohol enhance the progres-
sion of promoted and preneoplastic cells to the malignant
phenotype in appropriate tissues.
What new approaches shook! be explored for inhibiting
carcinogenesis?
New approaches to the inhibition of carcinogenesis include
the use of anti- initiators, antipromoters, and antiproliferative
agents that show promise for chemoprevention in humans
(1,4). Another approach is the interaction of early immune
response with phenotypically altered cells, an area of study
that has been almost totally neglected. The results of so-
phisticated experimental studies using ultraviolet irradiation
of skin and analysis of host immune and nonimmune cell
distribution in skin lesions indicate that complex interactions
occur between immune cells and damaged normal cells (5,6).
Undoubtedly, subtle changes in host immune status occur in
response to the first biochemical membrane lesion or altered
cytokine release, and crude pharmacologic approaches can
be used to interfere with these processes. It is likely that with
more detailed understanding of the biological battlefield,
specific pharmacologic or biologic agents will be developed
to interfere with the escape of early precancerous growth
from host immune control without producing irreversible
effects on the host immune system.
What is the natural history of premalignant conditions?
An understanding of the biology of preneoplastic lesions
should provide important information about carcinogenesis
in humans. The study of the progression of carcinogenesis is
relatively new and is essentially confined to animal cutaneous
models. Except for cervical dysplasia (7), very little is known
about the biology of premalignant conditions in humans.
Investigators have begun to study the precursive biology
of cutaneous melanoma (8), esophageal cancer (9), and to
a lesser extent, colon cancer (70), but virtually nothing is
known about the biology of these lesions or of such lesions
as oral leukoplakia, bronchial metaplasia, gastric metaplasia,
and actinic keratosis.
Are there good intermediate markers for cancer or
cancer risk?
The extensive time required for progression from the dam-
aged cell to cancer in humans has made the study of inter-
mediate biochemical markers attractive. However, a major
problem is that we do not know if any of them are valid in-
dicators of cancer risk or development Most investigators
have used markers to measure abnormalities by analysis of
DNA content or cytogenetic study or by indirect [(ornithine
decarboxylase or protein kinase C (PKC)] or direct (Ki67
antibody, thymidine labeling, or mitotic index) estimation of
proliferation. Chromosomal abnormalities have been predic-
tive of malignant outcome, but in general, they have been
identified at late stages of the disease (11,12). Although sev-
eral complex studies have used intermediate markers for
colonic cell proliferation, including favorable modulation by
calcium, it has not been demonstrated that these changes are
indicators of cancer risk or development (10,13,14). The
concept of intermediate markers is valuable for the study of
human neoplasia and of the modulating effects of chemo-
prevention agents, but more detailed investigations in animal
models and in human disease are needed to validate the
approach.
What are desirable properties of a chemoprevention
agent in humans?
The optimal chemoprevention agent would be nontoxic,
highly efficacious, easily measurable in serum and tissue, and
readily available. For the most part, dietary components such
as 0-carotene, a-tocopherol, and vitamin C fill this bill. Other
dietary elements such as selenium appear to have a steep ef-
ficacy/toxicity ratio. With few exceptions-, the pharmacolog-
ical compounds proposed as chemopreventive agents have
side effects that are dose related. The acceptability of side
effects depends on the nature of the condition being stud-
ied. An individual with familial polyposis may be willing
to accept considerable side effects from a chemoprevention
agent In contrast, a person 55 years of age who has had
one polyp removed in the past year and is asked to join a
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chemoprevention trial to prevent polyp recurrence may ex-
press considerable reservations if any side effects from a drug
are expected. One way to reduce side effects is to determine
the lowest dose at which an agent will produce a significant
and relevant biochemical or biological effect Careful phase
I studies with modulation of biological or biochemical end
points in relevant tissues are needed to provide the basis for
planning future chemoprevention trials.
What is the biological rationale for development of
chemoprevention agents?
There are a number of ways in which chemoprevention
agents can be viewed. One possible unified approach is
shown in figure 2. The common strategy for chemopreven-
tion at the cellular level is modulation of the key regula-
tory pathways, most notably, signal transduction and control
mediated by the phosphatidylinositol cascade, the cyclic nu-
cleotide pathway, and polyamine regulation. The intricacies
of these regulatory controls have been described in detail
(15-IT). The purpose of this discussion is to point out new
possibilities for chemoprevention strategies in the future.
A multitude of growth factors mediate the effects of these
regulatory controls by signal transduction via the phosphatidyl-
inositol (fig. 2, Al) cascade or the cyclic nucleotide (fig. 2,
A2) pathway. Undoubtedly, abnormalities in growth factor
production, growth factor receptor function, or integration
of the response will be found to be early changes in ma-
lignant transformation. Abundant data indicate that growth
factors can either produce or inhibit proliferation in the same
cells, depending on the biochemical and cellular milieu (75).
The development of signal analogs or inhibitors that differen-
tially affect receptor function should lead to the availability
of new chemoprevention agents as well. Propagation of the
signal via the phosphatidylinositol pathway requires a steady
source of inositol (fig. 2B). The regeneration of inositol
from inositol-1-phosphate is selectively inhibited by lithium
and results in abrogation of signal responses (19). Lithium
carbonate (Eskalith) has been widely used as a drug for
manic-depressive illness; the pharmacology is well known,
and side effects closely correlate to serum levels. Conse-
quently, further exploration of lithium as a potential chemo-
prevention agent is warranted.
The role of PKC in modulating cellular responses has
been extensively studied, and the enzyme has a multiplic-
ity of secondary modifications via phosphorylation. With
the recent identification of these numerous subtypes of
PKC, the possibility of interactions and modifications of
key enzymes and receptors is nearly limitless. Because
12-0-tetradecanoylphorbol-13-acetate (TPA) has been iden-
tified as the ligand for PKC, the design of specific inhibitors
seems possible and likely. Recent studies with the nonphor-
bol tumor promoter bryostatin suggest that the control of the
enzyme is complex and the opportunity to develop specific
modulators extensive (20). A number of nonspecific regu-
lators (anti-inflammatory steroids) and selective regulators
[H-series derivative (isoquinolinesulfonamides) and palmi-
toyl carnitine] of PKC have been identified and studied. It
may be useful to study the effects of carnitine (fig. 2C),
since the action of this natural substrate for palmitoyl carni-
tine and lipid biosynthesis has been well studied (21). Addi-
tionally, carnitine is commercially available for the treatment
of inherited carnitine deficiencies.
An important intermediate in the phosphatidylinositol cas-
cade, arachidonic acid, is the source of prostanoids, which
are major stimulators of cellular proliferation in the cells
of many tissues. Many nonsteroidal anti-inflammatory com-
pounds inhibit prostaglandin synthesis. A particularly useful
compound is proxicam (fig. 2D), which has been active as
a chemoprevention agent in animal systems (22). The clin-
ical experience with this drug has been extensive, and the
spectrum of side effects at different doses is well defined.
One of the sentinel regulatory enzymes that undergoes
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Figure 2. Diagram
of a biological strat-
egy for chemopre-
vention. Some po-
tential inhibitors of
carcinogenesis: Al
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cam; E, DFMO; and
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modification by PKC is ornithine decarboxylase, an impor-
tant key enzyme in the polyamine synthesis pathway. The
role of polyamine synthesis in cellular regulation has been
extensively studied and recently reviewed (76). An impor-
tant step in understanding the role of polyamines in cellular
growth was the synthesis of an enzyme-activated irreversible
inhibitor of ornithine decarboxylase activity, difluoromethyl-
ornithine (DFMO). This compound has been shown to be
an inhibitor in all of the animal systems tested, whether it
was applied topically or administered systemically. It has
also been demonstrated that low doses of DFMO inhibit
TPA-promoted human skin ornithine decarboxylase (23).
Since this compound is almost nontoxic at low concentra-
tions, its use as a chemoprevention agent in humans should
be widely explored (fig. 2E). We have just started studies
with DFMO (Eflornithine) in patients with oral leukoplakia
and Barrett's esophagus and eagerly await the results.
The cyclic nucleotide pathway has been a rich target for
study of differentiation and proliferation in normal and ab-
normal cells (7 7). In some systems, merely raising the cAMP
levels by using theophylline (or derivatives) to inhibit the
breakdown of cyclic nucleotide produces profound changes,
with marked inhibition of growth and terminal differentia-
tion. In other systems, no such effect is seen. Perturbation of
this critical pathway as a strategy for chemoprevention has
not been well studied at the experimental level. In view of
the rigid controls evidenced by the study of this pathway,
the development of modulators appears to be an important
chemoprevention strategy (fig. 2F). The real possibilities
for new and novel chemoprevention strategies based on an
appreciation of key regulatory events in the cell should be
evident
In the past decade, the results of epidemiologic studies and
clinical trials have provided the basis for a reliable scientific
strategy for early intervention against human cancers. In the
next decade, modern biology should also contribute informa-
tion critical to the success of that endeavor. Epidemiology
and biology as complementary underpinnings for chemopre-
vention in humans should become the order of the day.
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